Marco Boorsma, PhD
Marco is General Partner at Forbion and joined the team in 2007.
Marco has a background in molecular biology and biotechnology and brings operational and business development experience from both small and large businesses. He serves on the Board of RSPR Pharma and Prexton Therapeutics, and is Observer to the Board of Exosome Diagnostics and Oxyrane. He was instrumental in the start-up of Dezima Pharma and subsequently served on its Board. Dezima was sold to Amgen for up to USD1.5Bn in 2015. Marco also served on the Board of Akarna Therapeutics, which was sold in 2016 to Allergan for up to USD 1Bn after 6 months of investing.
Before joining Forbion Marco was Business Development Director at DSM Pharmaceutical Products, responsible for out-licensing of biomanufacturing technologies and securing and managing contract manufacturing projects. Prior to that Marco was a project manager and scientist responsible for process development and cGMP manufacturing of biopharmaceuticals. While at Cytos Biotechnology (Switzerland) Marco developed manufacturing processes for high-value biosimilar proteins.
After obtaining a master’s degree in molecular biology from the University of Groningen, Marco received his PhD in biotechnology from the ETH Institute for Technology in Zürich, Switzerland for his work on virus-based gene expression systems, partly in collaboration with the Laboratory of Molecular Biology of the Medical Research Counsil in Cambridge, UK.